Elevance Health (NYSE:ELV – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 37.200- for the period, compared to the consensus earnings per share estimate of 37.280. The company issued revenue guidance of -.
Elevance Health Trading Up 0.6 %
NYSE ELV traded up $2.94 during trading hours on Friday, reaching $535.17. The company had a trading volume of 874,644 shares, compared to its average volume of 1,331,405. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $124.10 billion, a P/E ratio of 20.23, a price-to-earnings-growth ratio of 1.18 and a beta of 0.84. The stock has a 50-day moving average of $529.51 and a 200 day moving average of $518.31. Elevance Health has a 1-year low of $431.38 and a 1-year high of $555.35.
Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share for the quarter, topping analysts’ consensus estimates of $9.99 by $0.13. The firm had revenue of $43.22 billion during the quarter, compared to analysts’ expectations of $42.99 billion. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The firm’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter last year, the company posted $9.04 EPS. As a group, research analysts anticipate that Elevance Health will post 37.25 earnings per share for the current fiscal year.
Elevance Health Announces Dividend
Analyst Upgrades and Downgrades
ELV has been the topic of several research reports. Mizuho increased their price target on shares of Elevance Health from $575.00 to $585.00 and gave the stock a buy rating in a research report on Wednesday, April 24th. Wells Fargo & Company decreased their price target on shares of Elevance Health from $600.00 to $593.00 and set an overweight rating for the company in a research note on Monday, July 22nd. JPMorgan Chase & Co. boosted their price objective on shares of Elevance Health from $628.00 to $631.00 and gave the company an overweight rating in a research note on Thursday, May 30th. Barclays dropped their price target on shares of Elevance Health from $621.00 to $611.00 and set an overweight rating on the stock in a research note on Thursday, July 18th. Finally, Truist Financial raised their price target on Elevance Health from $600.00 to $620.00 and gave the company a buy rating in a report on Monday, July 15th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Elevance Health has a consensus rating of Buy and an average target price of $604.29.
View Our Latest Analysis on Elevance Health
Insiders Place Their Bets
In other news, Director Robert L. Dixon, Jr. sold 305 shares of the business’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $506.76, for a total value of $154,561.80. Following the sale, the director now owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the business’s stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the sale, the director now owns 9,721 shares of the company’s stock, valued at $4,926,213.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Gail Boudreaux sold 34,000 shares of Elevance Health stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $500.98, for a total value of $17,033,320.00. Following the completion of the transaction, the chief executive officer now owns 126,709 shares in the company, valued at $63,478,674.82. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.
About Elevance Health
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Stories
- Five stocks we like better than Elevance Health
- What is a Bond Market Holiday? How to Invest and Trade
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What does consumer price index measure?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Insider Trades May Not Tell You What You Think
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.